Allele-specific real-time PCR system for detection of subpopulations of genotype 1a and 1b hepatitis C NS5B Y448H mutant viruses in clinical samples

Journal of Clinical Microbiology

Volumn 49, Issue 9, 2011, Pages 3168-3174

  Bae, Andrew S ^a   Ku, Karin S ^a   Miller, Michael D ^a   Mo, Hongmei ^a   Svarovskaia, Evguenia S ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTIDINE; NONSTRUCTURAL PROTEIN 5B; TEGOBUVIR; TYROSINE;

ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROCESS DEVELOPMENT; REAL TIME POLYMERASE CHAIN REACTION; REPLICON; VIRUS DETECTION; VIRUS GENE; VIRUS MUTANT; WILD TYPE;

AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; DRUG MONITORING; DRUG RESISTANCE, VIRAL; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; MUTANT PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; SELECTION, GENETIC; VIRAL NONSTRUCTURAL PROTEINS; VIROLOGY;

HEPATITIS C VIRUS;

EID: 80052256514     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00274-11     Document Type: Article

References (22)

1. Cooper, C., et al. 2009. Evaluation of VCH-759 monotherapy in hepatitis C infection. J. Hepatol. 51:39-46.
2. Curry, S., P. Qiu, and X. Tong. 2008. Analysis of HCV resistance mutations during combination therapy with protease inhibitor boceprevir and PEGIFN [alpha]-2b using TaqMan mismatch amplification mutation assay. J. Virol. Methods 153:156-162.
3. Forestier, N., et al. 2007. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 46:640-648. (Pubitemid 47436108)
4. Harris, J., et al. 2010. Abstr. 61st Annu. Meet. Am. Assoc. Study Liver Dis., abstr. 883.
5. Herring, B. L., R. Tsui, L. Peddada, M. Busch, and E. L. Delwart. 2005. Wide range of quasispecies diversity during primary hepatitis C virus infection. J. Virol. 79:4340-4346.
6. Kieffer, T. L., A. D. Kwong, and G. R. Picchio. 2010. Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs). J. Antimicrob. Chemother. 65:202-212.
7. Kuntzen, T., et al. 2008. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 48:1769-1778.
8. Kwong, A. D., L. McNair, I. Jacobson, and S. George. 2008. Recent progress in the development of selected hepatitis C virus NS3 · 4A protease and NS5B polymerase inhibitors. Curr. Opin. Pharmacol. 8:522-531.
9. Lawitz, E., et al. 2008. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. J. Hepatol. 49:163-169.
10. Le Pogam, S., et al. 2008. Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients. J. Antimicrob. Chemother. 61:1205-1216.
11. Lu, L., H. Mo, T. J. Pilot-Matias, and A. Molla. 2007. Evolution of resistant M414T mutants among hepatitis C virus replicon cells treated with polymerase inhibitor A-782759. Antimicrob. Agents Chemother. 51:1889-1896.
12. Mo, H., et al. 2011. Abstr. 46th Annu. Meet. Eur. Assoc. Study Liver, abstr. 1225.
13. Mo, H., et al. 2005. Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro. Antimicrob. Agents Chemother. 49:4305-4314.
14. Moser, M. J., et al. 2005. Quantifying mixed populations of drug-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 49: 3334-3340.
15. Naggie, S., K. Patel, and J. McHutchison. 2010. Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors. J. Antimicrob. Chemother. 65:2063-2069.
16. Palmer, S., et al. 2005. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J. Clin. Microbiol. 43:406-413.
17. Qi, X., et al. 2009. Development of a replicon-based phenotypic assay for assessing the drug susceptibilities of HCV NS3 protease genes from clinical isolates. Antiviral Res. 81:166-173.
18. Reesink, H. W., et al. 2010. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterology 138:913-921.
19. Soriano, V., M. G. Peters, and S. Zeuzem. 2009. New therapies for hepatitis C virus infection. Clin. Infect. Dis. 48:313-320.
20. Svarovskaia, E. S., et al. 2007. Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine. J. Acquir. Immune Defic. Syndr. 46:174-180.
21. Svarovskaia, E. S., et al. 2006. MultiCode-RTx real-time PCR system for detection of subpopulations of K65R human immunodeficiency virus type 1 reverse transcriptase mutant viruses in clinical samples. J. Clin. Microbiol. 44:4237-4241.
22. Thompson, P. A., R. A. Patel, K. R. Steffy, and J. R. Appleman. 2009. Abstr. 44th Annu. Meet. Eur. Assoc. Study Liver, abstr. 90.